Liver Enzyme Profile of Hepatitis B Positive Blood Donors in Enugu State University Teaching Hospital

Hepatitis B virus (HBV) remains a major global health problem. This is particularly seen through blood donation, where many carriers are asymptomatic and can unknowingly transmit the virus. This study addresses a gap in local data by investigating the liver enzyme profiles of HBV-positive blood donors at the Enugu State University Teaching Hospital. We conducted a descriptive, cross-sectional study from September to November 2024, enrolling 170 voluntary blood donors. Blood samples were screened for Hepatitis B surface antigen (HBsAg) using a rapid diagnostic strip, and the liver enzymes—aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP)—were measured using standard biochemical assays. Questionnaires were also used to collect socio-demographic data and assess HBV awareness.
The study found a 17.5% HBsAg seroprevalence among the 97 donors included in the final analysis. A high level of HBV awareness (81.4%) was observed, with most knowledge gained from health workers. The donor population was predominantly male (89.7%), and the highest prevalence of HBV-positive cases (54.6%) was in the 26–35 age group. The liver enzyme profiles of the 17 HBsAg-positive donors showed mildly elevated levels, particularly for ALP. The mean values were: AST 17.82 U/L (range 5.0–38.0), ALP 62.02 U/L (range 22.1–108.1), and ALT 11.12 U/L (range 4.0–26.0). These mild elevations suggest potential subclinical liver damage, consistent with either a mild acute or chronic viral hepatitis, emphasizing that even asymptomatic carriers can have subtle liver pathology. The findings highlight the critical need for continued rigorous screening and further clinical investigation of seropositive donors, including comprehensive follow-up and advanced testing (e.g., HBV DNA), to ensure transfusion safety and mitigate long-term health risks.

Hepatitis B Virus, Liver Enzyme Profile, Blood Donors, Seroprevalence, Transfusion Safety

1. Alao, F., Okwori, E. E., Egwu, C. O., & Audu, F. (2019). Seroprevalence of Hepatitis B surface antigen among blood donors in an urban area of North Central Nigeria. International Gastroenterology & Hepatology, 5(10), 830–839. [Google Scholar] [Crossref]

2. Albshri, M., Manikandan, P., Allahyani, M., Aljuaid, A., Almehmadi, M. M., Alzabeedi, K., Babalgaith, M., Alghamdi, M., Alharbi, F., & Alhazmi, M. (2023). The Prevalence of Transfusion-Transmitted Diseases Among Blood Donors in the Central Blood Bank in Makkah, Saudi Arabia. Cureus, 15(11), e48881. https://doi.org/10.7759/CUREUS.48881 [Google Scholar] [Crossref]

3. Balogun TM, Durojaiye IO, Sagoe A, Emmanuel S. Seroepidemiology of hepatitis-B surface antigenaemia in H. (This entry is incomplete and needs to be fully provided.) [Google Scholar] [Crossref]

4. Bosch, F.X, J. Ribes, M. Díaz, R. Cléries Primary liver cancer. (2019). Worldwide incidence and trends Gastroenterology, 127 (5) 5-16. [Google Scholar] [Crossref]

5. Burtis C and Bruns D (2017). Tietz Fundamentals of Clinical Chemistry. Walter Burns Saunders Company, USA, 684-892. [Google Scholar] [Crossref]

6. Buseri FI, Muhibi MA, Jeremiah ZA. (2009). Seroepidemiology of transfusion transmissible infectious diseases among blood donors in Osogbo, South-West Nigeria. Blood Transfusion. 7(4):293-299. [Google Scholar] [Crossref]

7. Conners, E.E., Panagiotakopoulos, L., Hofmeister, M.G. (2023). Screening and Testing for Hepatitis B Virus Infection. Centre for Disease Control Recommendations United States,7 2(1),1–25. [Google Scholar] [Crossref]

8. Doe, J., & Smith, A. (2020). Liver Enzyme Profiles and Hepatitis B in Blood Donors: A Comparative Study. Journal of Clinical Hepatology, 12(3), 200-215. [Google Scholar] [Crossref]

9. Ejele, O. A., Ojule, A. C., & Nwauche, C. A. (2021). Prevalence of Hepatitis B in blood donors in Port Harcourt, Nigeria. Nigerian Journal of Medicine, 20(4), 495-499. [Google Scholar] [Crossref]

10. Ganem, D., & Prince, A. M. (2014). Hepatitis B virus infection natural history and clinical consequences. New England Journal of Medicine, 350(11), 1118-1129. [Google Scholar] [Crossref]

11. Helen S., Donald M Jensen. (2010). Epidemiology of hepatitis B and C viruses. A global overview Clinics in liver disease, 14 (1), 1-21. [Google Scholar] [Crossref]

12. Hoofnagle, J. H. (2012). Course and outcome of Hepatitis B viral infection. Hepatology, 36(1), 201-210. [Google Scholar] [Crossref]

13. Lawal OA, Bakarey AS, Uche LN, Udeze AO, Okonko IO.2009 HBV infection among intending blood donors who incidentally tested positive for HIV antibodies in two blood banks in Ibadan, Nigeria. World Applied Science Journal. 1(2):97-107. [Google Scholar] [Crossref]

14. Luka SA, Ibrahim MB, IIiya SN. 2008 Seroprevalence of hepatitis B surface antigen among pregnant women attending Ahmadu University Teaching Hospital, Zaria, Nigeria. Nigerian Journal of Parasitology. 29(1): 38-41. [Google Scholar] [Crossref]

15. Lukhwareni A, Burnett RJ, Selabe SG, Mzileni MO, Mphahlele MJ. 2009 Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J Med Virol; 81(3):406-12. [Google Scholar] [Crossref]

16. Mehmet D, Meliksah E, Serif Y, et al.2005 Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Japanese Journal of Infectious Diseases; 58(1):15-19. [Google Scholar] [Crossref]

17. O’Brien, S. F., Reedman, C. N., Osiowy, C., Bolotin, S., Yi, Q. L., Lourenço, L., Lewin, A., Binka, M., Caffrey, N., & Drews, S. J. (2023). Hepatitis B Blood Donor Screening Data: An Under-Recognized Resource for Canadian Public Health Surveillance. Viruses, 15(2), 409. https://doi.org/10.3390/V15020409/S1 [Google Scholar] [Crossref]

18. Ren, W., Ren, J., Wu, Z., Shen, L., Shan, H., Dai, X., Li, J., Liu, Y., Qiu, Y., Yao, J., & Li, L. (2020). Long-term persistence of anti-HBs after hepatitis B vaccination among adults: 8-year results. Human Vaccines & Immunotherapeutics, 16(3), 687. https://doi.org/10.1080/21645515.2019.1666612 [Google Scholar] [Crossref]

19. Rizzo, G. E. M., Cabibbo, G., & Craxì, A. (2022). Hepatitis B Virus-Associated Hepatocellular Carcinoma. Viruses, 14(5), 986. https://doi.org/10.3390/V14050986 [Google Scholar] [Crossref]

20. Seto, W. K., Lo, Y. R., Pawlotsky, J. M., & Yuen, M. F. (2014). Chronic hepatitis B virus infection. The Lancet, 379(9820), 2129–2140. [Google Scholar] [Crossref]

21. Shepard, C. W., Simard, E. P., Finelli, L., Fiore, A. E., & Bell, B. P. (2016). Hepatitis B virus infection: Epidemiology and vaccination. Epidemiologic Reviews, 28(1), 112-125. [Google Scholar] [Crossref]

22. Tan, S. H. S., Wang, D. B., Tan, W. J., Allameen, N. A., & Fong, N. P. (2020). Facilitators and barriers of Hepatitis B screening and vaccination. Vaccine, 38(34), 5447–5453. https://doi.org/10.1016/j.vaccine.2020.06.045 [Google Scholar] [Crossref]

23. Thad Wilkins, Richard Sams, Mary Carpenter Hepatitis B: screening, prevention, diagnosis, and treatment. 2019 American family physician 99 (5), 314-323. [Google Scholar] [Crossref]

24. Tsai JF, Jeng JE Ho MS, Wang CS, Chang WY, Hsieh MY, Lin ZY and Tsai JH (1997) Serum alanine aminotransferase level in relation to hepatitis B and C virus infections among blood donors. The antomy of the Liver 17(1): 24-29. [Google Scholar] [Crossref]

25. Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH.2005 Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz. 2005 Feb;100(1):13-6. [Google Scholar] [Crossref]

26. W. H. Organization Global Hepatitis Report (2017). Centers for Disease Control and Prevention (U.S.) & International Federation of Red Cross and Red Crescent Societies. Blood donor counselling implementation guidelines. [Google Scholar] [Crossref]

27. WHO (2021). Prevention and Control of Viral Hepatitis Infection: Framework for Global Action, Guideline for the prevention, care and treatment of persons with chronic Hepatitis B infection. [Google Scholar] [Crossref]

28. W.H.O.E. Region, C. Hbv, and W.H.O.E. Region (2015). Hepatitis B in the WHO European Region KEY FACTS. [Google Scholar] [Crossref]

29. WHO (2025, July 23). Hepatitis B. WHO. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b [Google Scholar] [Crossref]

• Tribal Child Nutrition and Health in District of Sundargarh: A Public Health Review of ICDS Intervention
• Knowledge, Attitudes and Practices Towards Prostate Cancer Screening Amongst Men Aged 40-60 Years in The Buea Health District: A Cross-Sectional Study
• Compliance with JCI Protocols: A Focus on Employee Safety
• Influence and Involvement of Teachers in Menstrual Hygiene Management of Female Secondary School Students in Kogi State, Nigeria
• A Critical Evaluation of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana in Bihar